BioLineRx Reports First Quarter 2017 Financial Results
Tel Aviv, Israel, May 25, 2017 – BioLineRx Ltd. (NASDAQ/TASE: BLRX), a clinical-stage biopharmaceutical company focused on oncology and immunology, today reports its financial results for the first quarter ended March 31, 2017.
Highlights and achievements during the first quarter 2017 and to date:
Continued advancing the Company’s lead project, BL-8040, in an extensive clinical development program:
Announced plans to initiate Phase 3 pivotal study with BL-8040 as novel stem cell mobilization treatment for autologous bone-marrow transplantation in H2 2017, following successful meeting with the FDA.
Highlights and achievements during the first quarter 2017 and to date:
Continued advancing the Company’s lead project, BL-8040, in an extensive clinical development program:
Announced plans to initiate Phase 3 pivotal study with BL-8040 as novel stem cell mobilization treatment for autologous bone-marrow transplantation in H2 2017, following successful meeting with the FDA.